Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Licensed Influenza Vaccine 1

PreclinicalVaccine

1

Indications

2

Total Trials

0

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Influenza,humanCompleted

Influenza,humanPreclinical

Completed

Clinical

Trials by Indication[1]

COVID-191 trial

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

Completed· BioNTech logo

BioNTech·Phase 1/2·NCT06821061·2,650 enrolled

Influenza,Human1 trial

A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS

Completed· BioNTech logo

BioNTech·Preclinical·NCT06683352·1,353 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Licensed Influenza Vaccine 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Licensed Influenza Vaccine 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Licensed Influenza Vaccine 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Preclinical[1]
Company: BioNTech

Related News